RB Capital Management LLC Acquires 452 Shares of Merck & Co., Inc. (NYSE:MRK)

RB Capital Management LLC raised its holdings in Merck & Co., Inc. (NYSE:MRK) by 7.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,711 shares of the company’s stock after buying an additional 452 shares during the period. RB Capital Management LLC’s holdings in Merck & Co., Inc. were worth $566,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in MRK. CHICAGO TRUST Co NA grew its position in shares of Merck & Co., Inc. by 0.5% in the third quarter. CHICAGO TRUST Co NA now owns 49,159 shares of the company’s stock valued at $4,138,000 after purchasing an additional 234 shares during the last quarter. Ellis Investment Partners LLC grew its position in shares of Merck & Co., Inc. by 2.8% in the third quarter. Ellis Investment Partners LLC now owns 20,139 shares of the company’s stock valued at $1,683,000 after purchasing an additional 555 shares during the last quarter. Allworth Financial LP grew its position in shares of Merck & Co., Inc. by 1.9% in the third quarter. Allworth Financial LP now owns 6,278 shares of the company’s stock valued at $528,000 after purchasing an additional 119 shares during the last quarter. IMS Capital Management grew its position in shares of Merck & Co., Inc. by 2.6% in the third quarter. IMS Capital Management now owns 11,826 shares of the company’s stock valued at $996,000 after purchasing an additional 302 shares during the last quarter. Finally, Parisi Gray Wealth Management grew its position in shares of Merck & Co., Inc. by 3.1% in the third quarter. Parisi Gray Wealth Management now owns 5,213 shares of the company’s stock valued at $439,000 after purchasing an additional 159 shares during the last quarter. Hedge funds and other institutional investors own 74.97% of the company’s stock.

Shares of MRK stock traded up $0.08 during trading hours on Thursday, reaching $84.26. The company’s stock had a trading volume of 703,285 shares, compared to its average volume of 8,735,727. The firm’s 50 day simple moving average is $84.62 and its 200-day simple moving average is $82.22. The company has a market capitalization of $216.07 billion, a price-to-earnings ratio of 19.41, a PEG ratio of 1.71 and a beta of 0.53. Merck & Co., Inc. has a fifty-two week low of $66.10 and a fifty-two week high of $87.35. The company has a quick ratio of 0.92, a current ratio of 1.21 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.14. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The company’s revenue was up 12.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.06 EPS. Sell-side analysts predict that Merck & Co., Inc. will post 4.92 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Monday, October 7th. Investors of record on Monday, September 16th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.61%. The ex-dividend date of this dividend was Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio is currently 50.69%.

In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 6,427 shares of the stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now directly owns 103,223 shares in the company, valued at approximately $8,783,245.07. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.27% of the stock is owned by company insiders.

Several equities analysts have recently commented on MRK shares. Argus upped their target price on Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Credit Suisse Group reaffirmed a “buy” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, August 7th. Bank of America set a $97.00 target price on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, July 11th. Leerink Swann initiated coverage on Merck & Co., Inc. in a research report on Thursday, August 15th. They set an “outperform” rating and a $103.00 price target on the stock. Finally, Morgan Stanley increased their price target on Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, June 21st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $93.29.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: Are sell-side analysts objective?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.